Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma Research Limited (~292)

  Print      Mail a friend       Annual reports

Thursday 04 November, 2004

Antisoma Research Limited

Research Update

Antisoma telomere targeting agent stops tumour growth in prostate
cancer model

London UK, 4 November 2004 - Cancer drug developer Antisoma today
presents new data showing that one of its telomere targeting agents
(TTAs) rapidly blocks prostate tumour growth in a human xenograft
model. While in untreated control animals tumours grew to lethal size
within 10 days, animals given the TTA experienced a halt in tumour
growth at around day 7 and survived to the experiment's end on day
25. These findings extend the range of cancers shown to be
susceptible to Antisoma's TTAs and demonstrate that the drugs have
profound effects on tumour growth even when used as a sole treatment.

The presentation will be given by Antisoma's Head of Research,
Professor Lloyd Kelland, at the AACR Special Conference on The Role
of Telomeres and Telomerase in Cancer in San Francisco. It comes as
the Company, working with the Cancer Research UK Group led by
Professor Stephen Neidle at the London School of Pharmacy, nears
completion of work to select a lead candidate from the TTA programme
for clinical trials.

Professor Kelland commented "What's really exciting about these TTAs
is the speed of their anti-tumour effects. We're not having to wait
for many rounds of cell division before the effects kick in, which
was a major concern with earlier drugs that were pure telomerase

| Enquiries:                                |                       |
|                                           |                       |
| Antisoma plc                              |                       |
| Daniel Elger, Head of Corporate           | Tel: +44 (0) 7909 915 |
| Communications                            | 068                   |
| Office switchboard                        | Tel: +44 (0) 20 8799  |
|                                           | 8200                  |
|                                           |                       |
| Financial Dynamics                        |                       |
| Julia Phillips                            | Tel: +44 (0)20 7831   |
|                                           | 3113                  |
|                                           |                       |
| De Facto Communications (mainland Europe) |                       |
| Richard Anderson                          | Tel: +44 (0)20 7490   |
|                                           | 1000                  |
|                                           |                       |

Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Notes for Editors:

About telomere targeting agents (TTAs)
Antisoma has three drugs in clinical trials and three priority
preclinical projects, one of which is the TTA programme. The TTAs
under development at Antisoma were invented by Professor Stephen
Neidle at the Institute of Cancer Research and the London School of
Pharmacy. They were licensed by Antisoma through Cancer Research
Technology, which is part of Cancer Research UK.

Telomeres are protective regions found at the ends of chromosomes
(the structures into which DNA is packaged in each cell of the body).
In normal cells, they shorten slightly with each round of cell
division until they become critically short, causing the cell to
enter the self-destruct programme of apoptosis. Most cancer cells
make the enzyme telomerase, which maintains the length of telomeres
and allows the cells to avoid apoptosis. A number of drugs have been
developed that inhibit telomerase. These are generally characterised
by a slow onset of action because they require rounds of cell
division to 'run down' the telomeres to the point where apoptosis
ensues. TTAs by contrast act more rapidly, binding to the telomere
itself and destabilising it. One clear effect is the uncapping of
chromosome ends leading to lethal end-to-end chromosome fusions. The
action of TTAs is believed to involve prevention of telomerase
binding to the telomere. However, it must have other facets because
the drugs show broad effectiveness against cancer cell lines,
including the minority that use alternative, non-telomerase
mechanisms to maintain their telomeres.

About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. The Company
fills its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions.  Its core activity is the preclinical and
clinical development of these drug candidates. Antisoma forms
partnerships with pharmaceutical companies to bring its products to
market.  In November 2002, Antisoma formed a broad strategic alliance
with Roche to develop and commercialise products from Antisoma's
pipeline. Please visit for further information about



a d v e r t i s e m e n t